Alnylam Pharmaceuticals Stock Options Expiring on 17th of January

ALNY Stock  USD 276.73  2.03  0.73%   

Alnylam Total Stockholder Equity

Total Stockholder Equity

(241.05 Million)

Alnylam Pharmaceuticals reported Total Stockholder Equity of (253.74 Million) in 2024

Alnylam Pharmaceuticals Corporate Management

Saraswathy NochurEquity DiversityProfile
Indrani JDExecutive SecretaryProfile
Evan LippmanChief OfficerProfile
JD EsqChief SecretaryProfile
Piyush JDChief OfficerProfile
Alfred BoyleChief OfficerProfile
Timothy MainesChief OfficerProfile

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.